Looking at the development of pharmaceuticals, new drug development has gone through different stages of research and manufacturing including herbal medicines, chemical drugs, and biologics. The 'decryption' of the human genome draft in 2000 marked the entry of pharmaceutical companies into the era of translational medicine and precision medicine. After 2010, the emergence of AI technology has triggered a paradigm shift in new drug screening and development. The development and production of drugs is a rigorous and lengthy process, and overall, the birth and iteration of disruptive technologies in the pharmaceutical field are relatively slow.
Frost & Sullivan continues to pay attention to emerging technologies in the field of drug development and production, and hereby publishes the 'Drug 3D Printing Industry Report'. This report is the first multi-dimensional industry analysis of drug 3D printing, providing the most comprehensive and in-depth analysis at the levels of technological development, industry trends, and commercial potential. The report points out that drug 3D printing technology will advance the digitization and intelligence of the pharmaceutical industry, become an accelerator for modern drug research and development by pharmaceutical companies, and an advanced means of drug manufacturing.
